ELISA-Based Neonatal Screening Line Offers Menu of Eight Kits
By LabMedica International staff writers Posted on 25 Jun 2018 |
Image: The new line of ELISA tests designed for neonatal screening is based on Dry Blood Spot (DBS) technology and comprises a menu of eight kits (Photo courtesy of Calbiotech).
A recently released line of ELISA tests for neonatal screening is based on Dry Blood Spot (DBS) technology and comprises a menu of eight kits. The kits are the newest diagnostic assays being introduced by Calbiotech (Spring Valley, CA, USA).
The Calbiotech catalog features over 200 diagnostic products including a full range of ELISA-based immunoassay kits focused on areas such as: thyroid hormones, fertility, steroids, diabetes, allergy, anemia, growth markers, bone metabolism, inflammatory diseases, cancer, cardiac diseases, drugs of abuse, autoimmune disorders, infectious diseases, and neonatal screening.
In addition, Calbiotech's Custom Development team crafts custom assays in a "Pipeline to Production" approach. To this end, the company has developed coated microplates, reagents, buffers, and other components for pharmaceutical companies, universities, and research centers in the United States and around the world. Rounding out its contribution to the diagnostics industry, Calbiotech also offers contract-manufacturing services that cover immunoassay development (microplates and magnetic beads), bulk coating of microplates, reagent preparation, including bottling, labeling and packaging.
The Calbiotech catalog features over 200 diagnostic products including a full range of ELISA-based immunoassay kits focused on areas such as: thyroid hormones, fertility, steroids, diabetes, allergy, anemia, growth markers, bone metabolism, inflammatory diseases, cancer, cardiac diseases, drugs of abuse, autoimmune disorders, infectious diseases, and neonatal screening.
In addition, Calbiotech's Custom Development team crafts custom assays in a "Pipeline to Production" approach. To this end, the company has developed coated microplates, reagents, buffers, and other components for pharmaceutical companies, universities, and research centers in the United States and around the world. Rounding out its contribution to the diagnostics industry, Calbiotech also offers contract-manufacturing services that cover immunoassay development (microplates and magnetic beads), bulk coating of microplates, reagent preparation, including bottling, labeling and packaging.
Latest Molecular Diagnostics News
- Blood Proteins Could Warn of Cancer Seven Years before Diagnosis
- New DNA Origami Technique to Advance Disease Diagnosis
- Ultrasound-Aided Blood Testing Detects Cancer Biomarkers from Cells
- New Respiratory Syndromic Testing Panel Provides Fast and Accurate Results
- New Synthetic Biomarker Technology Differentiates Between Prior Zika and Dengue Infections
- Novel Biomarkers to Improve Diagnosis of Renal Cell Carcinoma Subtypes
- RNA-Powered Molecular Test to Help Combat Early-Age Onset Colorectal Cancer
- Advanced Blood Test to Spot Alzheimer's Before Progression to Dementia
- Multi-Omic Noninvasive Urine-Based DNA Test to Improve Bladder Cancer Detection
- First of Its Kind NGS Assay for Precise Detection of BCR::ABL1 Fusion Gene to Enable Personalized Leukemia Treatment
- Urine Test to Revolutionize Lyme Disease Testing
- Simple Blood Test Could Enable First Quantitative Assessments for Future Cerebrovascular Disease
- New Genetic Testing Procedure Combined With Ultrasound Detects High Cardiovascular Risk
- Blood Samples Enhance B-Cell Lymphoma Diagnostics and Prognosis
- Blood Test Predicts Knee Osteoarthritis Eight Years Before Signs Appears On X-Rays
- Blood Test Accurately Predicts Lung Cancer Risk and Reduces Need for Scans